ID   1351-mel
AC   CVCL_A1DS
SY   1351-MEL
DR   Wikidata; Q102113420
RX   PubMed=9670966;
CC   From: Rosenberg, Steven A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA.
CC   HLA typing: A*01,03; B*08,47; C*06,07 (PubMed=9670966).
CC   Derived from site: Metastatic; Not specified.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 10-09-24; Version: 5
//
RX   PubMed=9670966; DOI=10.4049/jimmunol.161.2.877;
RA   Bettinotti, Maria P.
RA   Kim, Christina J.
RA   Lee, Kang-Hun
RA   Roden, Matthew
RA   Cormier, Janice N.
RA   Panelli, Monica C.
RA   Parker, Kenneth K.
RA   Marincola, Francesco M.
RT   "Stringent allele/epitope requirements for MART-1/Melan A
RT   immunodominance: implications for peptide-based immunotherapy.";
RL   J. Immunol. 161:877-889(1998).
//